Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AB-729 is a subcutaneously-delivered RNAi therapeutic specifically designed to reduce all HBV viral antigens, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to virus.
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AB-729 is an RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to...
Brand Name : AB-729
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 20, 2022
Lead Product(s) : AB-729,Vebicorvir,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Assembly Biosciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ABI-H0731 (Vebicorvir) a first-generation selective inhibition of HBV DNA replication core protein, has demonstrated effective antiviral activity in chronic hepatitis B patients.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 08, 2022
Lead Product(s) : Vebicorvir,ATI-2173,Tenofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Clevudine Monophosphate Prodrug,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ATI-2173, once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate, only active site polymerase inhibitor nucleotide for HBV in clinical development.
Brand Name : ATI-2173
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 26, 2022
Lead Product(s) : Clevudine Monophosphate Prodrug,Tenofovir,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones
Details : ABI-H0731 (Vebicorvir), is a first-generation core inhibitors has been shown to be well-tolerated and statistically superior in antiviral activity in hepatitis B virus DNA suppression.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2022
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,Entecavir,Pegylated-interferon Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®
Details : ABI-H0731, a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity in chronic hepatitis B (CHB) patients also exhibited selective inhibition of HBV DNA replication.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2021
Lead Product(s) : Vebicorvir,Entecavir,Pegylated-interferon Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ATI-2173,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ATI-2173 has, to date, demonstrated a generally well-tolerated safety profile, leveraging a unique ASPIN mechanism in clinical development to empower combination therapy.
Brand Name : ATI-2173
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 19, 2021
Lead Product(s) : ATI-2173,Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Antios Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Plasma Cmin values for VBR, 2158, and 3733 are significantly above protein-adjusted EC50 values for antiviral activity, and plasma Cmin values of 2158 and 3733 are significantly above protein-adjusted EC50 values for cccDNA prevention.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2021
Lead Product(s) : Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sequence analyses were conducted for virologically-suppressed patients with chronic HBV enrolled in the Phase 2 Study 201 and open-label extension Study 211 of VBR in combination with a nucleos(t)ide reverse transcriptase inhibitor (NrtI) who discontinue...
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2021
Lead Product(s) : Vebicorvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy.
Brand Name : ABI-H0731
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2021
Lead Product(s) : Vebicorvir,AB-729,Entecavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BeiGene
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?